Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids - 2Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- 3Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- 4Two UN peacekeepers killed in explosion in Lebanon
- 5Flu season is ramping up, and some experts are "pretty worried"
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
- 'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- Journey through Pages: A Survey of \Plunging into Scholarly Universes\
- the Kinds of Thailand: Decision in favor of Your Number one Thai Dish!
- Exploring ways to reduce the impact of space junk on Earth
- Ancient fire discovery marks significant milestone in human history
